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1. Introduction
Vitiligo is an acquired, non-contagious disease in which progressive, patchy loss of pigmen‐
tation from the skin, overlying hair and oral mucosa results from the loss of melanocytes from
the involved areas [1]. Clinically, two large subsets of vitiligo are distinguished namely focal
or segmental vitiligo and non-segmental or generalised vitiligo [2]. Focal vitiligo presents with
a limited number of small lesions while segmental vitiligo is typified by an asymmetric
distribution involving segments of the skin surface, sometimes in a dermatomal fashion, by
depigmented macules. Non-segmental vitiligo corresponds to all generalised, usually sym‐
metrical, forms including acrofacial vitiligo. The course of the disease is unpredictable but is
often episodically progressive with phases of stabilised depigmentation. Extending vitiligo
with enlarging macules or the development of new lesions is classified as the active form of
the disease [3].
Although vitiligo might be viewed as minor disorder, skin depigmentation can cause psycho‐
logical stress in patients with respect to self-esteem and social interactions. This is particularly
true for individuals with deeply pigmented skin [4], and for women who in some cultures face
social and marital stigma [5]. The prevalence of vitiligo has been reported to be 0.5 to 1% of
the world population [6,7]. In India, the prevalence varies from 0.5 to 2.5 % [8], although the
states of Gujarat and Rajasthan have a prevalence of 8.8% [9]. Vitiligo affects all with no
predilection for gender or race. The disease usually starts in childhood or young adulthood:
the clinical manifestation begins before 20 years of age in 50% of cases, while in 25% of cases
the onset is before the age of 14 years [10].
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Many factors have been implicated in the aetiology and pathogenesis of the vitiligo including
infections [11], stress [12], neural abnormalities [13], defective melanocyte adhesion [14], and
genetic susceptibility (Figure 1) [15]. The biochemical hypothesis argues that melanocyte
destruction is due to the accumulation of toxic metabolites from melanogenesis, the break-
down of free-radical defence and an excess of hydrogen peroxide [16-18]. In addition, many
studies have indicated a role for both cellular [19] and humoral [20] immunity in the patho‐
genesis of vitiligo. This chapter will focus on the available evidence which supports the
involvement of autoimmunity in the aetiology and pathogenesis of vitiligo.
Figure 1. The generation of autoimmune responses against melanocytes in vitiligo. Depigmentation in vitiligo re‐
sults from a hyperactive response of the immune system against melanocytes. A complex interaction of immune cells
and immuno-genetic factors is the most likely aetiology. In particular, defects of T cell subsets as well as altered mela‐
nocyte antigens may give rise to increased autoreactive CD8+and CD4+T cells and the generation of anti-melanocyte
autoantibodies. The triggering factors involved in generation of autoimmunity in vitiligo patients are still not clearly
defined, although physical trauma and melanocyte oxidative stress have been implicated.
2. Association with autoimmune diseases
Vitiligo is frequently associated with other autoimmune disorders, particularly autoimmune
thyroid disease [21]. Patients with vitiligo are also more likely to suffer from autoimmune
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conditions than those in the general population [22]. For example, a survey of more than 2,600
unselected Caucasian vitiligo patients indicated elevated frequencies of autoimmune thyroid
disease, Addison’s disease, systemic lupus erythematosus and pernicious anaemia, and,
indeed, approximately 30% of patients were affected by at least one other autoimmune disease
[23]. Furthermore, the same autoimmune diseases were found at an increased prevalence in
the first-degree relatives of vitiligo patients [23] and in multiplex vitiligo families [24]. Such
findings indicate that vitiligo can be part of a specific group of autoimmune diseases to which
individuals can be genetically predisposed, and are also evidence for its autoimmune patho‐
genesis.
3. Immuno-regulatory genes
The involvement of immune-regulatory genes with vitiligo development has been extensively
documented [15]. For example, the association of certain major histocompatibility complex
(MHC) alleles with vitiligo has suggested an important link between the aetiology of the
disease and aberrant presentation of self-antigens to the immune system. Most recently, alleles
of human leukocyte antigen (HLA) genes HLA-A*33:01, HLA-B*44:03, and HLA-DRB1*07:01
have been reported to be significantly more prevalent in Indian vitiligo patients as compared
with healthy controls [25]. In the European-derived white population, vitiligo shows primary
association with HLA-A in the class I region [26], specifically HLA-A*02:01 [27], and in the class
II region upstream of HLA-DRA and located between HLA-DRB1 and HLA-DQA1. Further‐
more, studies of Chinese have shown MHC associations in the class I region, between HLA-
B and HLA-C [28] and in the class III region [29].
Other immune-regulatory genes that contain single nucleotide polymorphisms associated
with vitiligo susceptibility include PTPN22 (lymphoid-specific protein tyrosine phosphatase,
non-receptor type 22), IL2RA (interleukin-2 receptor alpha chain), UBASH3A (ubiquitin-
associated and SH3 domain–containing A protein), and C1QTNF6 (C1q and tumour necrosis
factor–related protein) [26].
4. Immunological features of melanocytes
Several studies have shown abnormal expression of MHC class II antigen HLA-DR and
increased expression of intercellular adhesion molecule-1 (ICAM-1) by perilesional melano‐
cytes in vitiligo compared with melanocytes from normal skin [30-32]. These molecules have
important roles in antigen presentation and in the activation of T helper cells, so their expres‐
sion by melanocytes could contribute to the anti-melanocyte cellular immune responses that
are observed in vitiligo [19,33].
Both vitiligo and normal melanocytes are also capable of expressing MHC class I molecules
[31], which could allow interaction with destructive cytotoxic T cells. Indeed, melanocytes have
an antigen processing and presenting capability which can make them target cells for T cell-
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mediated cytotoxicity [34]. Finally, in perilesional vitiligo biopsies, melanocytes express
macrophage markers CD68 and CD36 [32] and reduced levels of membrane regulators of
complement activation, including decay acceleration factor and membrane cofactor protein
[35], which suggests a vulnerability of these cells to attack by macrophages and the comple‐
ment system, respectively.
5. Autoantibodies
Melanocyte autoantibodies have been detected in the sera of vitiligo patients at a significantly
higher frequency than in healthy individuals [20,36]. They are associated with the extent of
vitiligo, being present in 93% of patients with 5-10% of skin area involvement, and in 50% of
patients with less than 2% of skin depigmentation [37]. In addition, patients with active vitiligo
have increased levels of melanocyte autoantibodies compared to those with stable disease
[38,39]. Characterisation of melanocyte autoantibodies has demonstrated that they belong to
the subclasses IgG1, IgG2 and IgG3 [40], although studies have also found that IgA levels of
melanocyte autoantibodies are associated with disease activity [41]. Several melanocyte-
specific autoantibody targets have been identified including tyrosinase [42-44], tyrosinase-
related protein (TRP)-1 [45], dopachrome tautomerase (or TRP-2) [46,47], PMEL [48] and GTP-
binding protein Rab38 [49].
Autoantibodies against targets not specifically expressed by melanocytes have also been
detected in patients with vitiligo including the melanin-concentrating hormone receptor 1,
gamma-enolase, alpha-enolase, heat-shock protein 90, osteopontin, ubiquitin-conjugating
enzyme, translation-initiation factor 2, tyrosine hydroxylase and laminA [49-51]. In addition,
organ-specific autoantibodies, particularly against the thyroid, adrenal glands, gastric parietal
cells, and pancreatic islet cells are commonly found in vitiligo patients [52], along with anti-
nuclear autoantibodies and IgM-rheumatoid factor [53]. Keratinocyte autoantibodies which
correlate with vitiligo extent and activity have been reported [54].
With respect to pathogenicity, vitiligo patient autoantibodies can mediate complement
damage and antibody-dependent cellular cytotoxicity against melanocytes and melanoma
cells in vitro and in vivo [55-57]. Passive immunisation of nude mice grafted with human skin
has also indicated that IgG from vitiligo patients can induce the destruction of melanocytes
[58]. Furthermore, melanocyte autoantibodies from vitiligo patients can induce HLA-DR and
ICAM-1 expression on and release of interleukin (IL)-8 from melanocytes [59]. Such changes
enhance the antigen-presenting activity of melanocytes allowing antigen-specific immune
effector cell attack. More recent work has found that 69% of vitiligo patient sera tested induced
melanocyte detachment in a reconstructed epidermis model, although this was unrelated to
either the extent or the activity of the disease [60]. Finally, melanocyte autoantibodies isolated
from vitiligo patients, but not from healthy controls, are able to penetrate cultured melanocytes
and trigger them to engage in apoptosis [61].
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6. CD4+helper and CD8+cytotoxic T cells
The first evidence for a possible role for T cells in the pathogenesis of vitiligo came from studies
on inflammatory vitiligo [62]. Since then, circulating autoreactive CD8+cytotoxic T that
recognise melanocyte antigens (MART1, PMEL and tyrosinase) have been detected in vitiligo
patients [33,63-66]. Peripheral CD8+T cells are more prevalent in active cases of vitiligo as
compared to stable cases, and their frequency correlates with the extent of depigmentation
[53,67]. They also express high levels of the skin-homing receptor cutaneous lymphocyte-
associated antigen and display cytotoxic reactivity towards melanocytes [33].
Histological studies of skin biopsies from vitiligo patients have demonstrated that infiltrating
cytotoxic and helper T cells are most prominent at the periphery of vitiligo lesions [32,68].
Moreover, a significant increase in the number of CD4+and CD8+T cells are detected in the
marginal skin in both stable and active vitiligo cases [69]. These perilesional T cells exhibit a
predominantly type-1-like cytokine secretion profile of tumour necrosis factor (TNF)-alpha
and interferon (IFN)-gamma, the latter enhancing T cell trafficking to the skin by increasing
ICAM-1 expression on target cells [70,71]. The majority of infiltrating T cells are activated, as
indicated by the expression of the MHC class II antigen HLA-DR [32,68] and the presence of
granzyme B+and perforin+cytotoxic T lymphocytes [32]. There is also evidence for down-
regulation of the T helper 2 cell-dependent CDw60 molecules in the vitiliginous epidermis.
This observation correlates with infiltrating T cells exhibiting a T helper 1 cell-type cytokine
production pattern consistent with cell-mediated organ-specific autoimmunity [72].
Using a skin explant model to investigate the effector functions of perilesional CD8+T cells, the
latter, which are enriched for cytotoxic T lymphocytes that recognise melanocyte antigens
(MART1, PMEL and tyrosinase), infiltrate normally pigmented skin and eradicate melanocytes
[19]. The capacity of cytotoxic T cells for damaging melanocytes has also been observed in an
experimental murine model of vitiligo: melanocytes were destroyed by CD8+T cells recognis‐
ing a single H2-Kb-binding peptide derived from dopachrome tautomerase [73].
7. T helper 17 cells
Increased numbers of T helper 17A+cells are found in the leading edge of vitiligo lesions as
shown by immunohistochemistry and immunofluorescence [74,75]. Elevated levels of IL-17A
mRNA are also present in the same locality [75], evidence that signifies active T helper 17 cells
in vitiligo lesions. In vitro, T helper 17 cell-related cytokines directly affect melanocyte activity
and function, including the down-regulation of melanin production and the shrinkage of
melanocytes [74]. In terms of the local cytokine network in the skin, IL-17A dramatically
induces production of IL-1beta, IL-6, and TNF-alpha by skin-resident cells such as keratino‐
cytes and fibroblasts [74].
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8. Regulatory T cells
Natural Treg cells play a key role in maintaining peripheral tolerance through the active
suppression of self-reactive T cell activation and expansion [76], thereby preventing the
development of the autoimmune responses. To date, several studies have indicated perturba‐
tions in Treg cell numbers and/or function in vitiligo patients [67,77-79]. Such alterations might
lead to the reported higher levels and activation of cytotoxic T cells in individuals with the
disease [67,77].
Assessment of circulating Tregs by flow cytometric analysis has revealed a decrease in their
numbers in vitiligo patients compared to controls [67,77,78]. Reduced peripheral Treg cell
numbers have also been reported in early age-of-onset patients (1-20 years) compared to those
with late onset vitiligo, and decreased circulating Treg cell counts have been demonstrated in
patients with active vitiligo as compared to those with stable disease [67]. Moreover, a striking
reduction in the number of Tregs in the marginal and lesional skin of vitiligo patients has been
observed [69,80]. Interestingly, some studies have demonstrated that peripheral or lesional
skin CD4+CD25+FoxP3+Treg cell numbers remain unaltered in vitiligo [81-83], and even that
either may be increased [67,84]. Interestingly, discrepancy between the relative abundance of
Treg cells present in the circulation of vitiligo patients as compared to their skin was reported
to be due to reduced expression of the chemo-attractant CCL22 within vitiligo patient skin so
impairing migration of Tregs into the tissue [83].
As well as defects in Treg cell numbers, their function can also be impaired in vitiligo patients.
Indeed, the suppressive effects of Tregs in vitiligo cases are significantly reduced as indicated
by their impaired ability to inhibit proliferation and cytokine production from autologous
CD8+T cells [77,78]. In line with this, the expression of FoxP3 (the dedicated mediator of the
genetic program governing Treg cell development and function) in CD4+CD25hi Tregs is
significantly decreased in vitiligo patients compared to controls [67]. Moreover, the mean
percentage area of positive immunostaining in skin biopsies and peripheral blood levels of
FoxP3 are significantly lower in vitiligo patients compared to controls [85]. Vitiligo area scoring
index, vitiligo disease activity and stress score also correlate negatively with FoxP3 levels [85].
The expression of CTLA-4 (a T cell surface molecule involved in regulation of T cell activation)
is also decreased in vitiligo patients, an impairment that could perturb the normal suppressive
capacity of Treg cells [86]. Furthermore, decreased serum and tissue levels of transforming
growth factor (TGF)-beta (important for imposing a Treg cell phenotype) are observed in
individuals with vitiligo [87]. Reduced levels of TGF-beta also correlate with increased disease
activity [88] and the percentage of involved body area [89]. Moreover, lowered IL-10 (contrib‐
utes to Treg cell-mediated immunosuppression) levels are present in active cases of vitiligo
[88,90]. Finally, and importantly, in a mouse model of vitiligo, the adoptive transfer of
melanocyte-specific Tregs was found to induce a lasting remission of the disease [91], thus
proposing Treg cells as a potential therapeutic target.
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9. Macrophages
Macrophage infiltration has been demonstrated in vitiligo lesions, with increased numbers
present in perilesional compared with normal skin [32,92]. There is evidence that macrophages
are involved in the clearing of apoptosed melanocytes from the skin in vitiligo patients [93].
In addition, macrophages expressing activating Fc-gamma receptors have been shown to
mediate depigmentation in a mouse model of autoimmune vitiligo [94]. Moreover, macro‐
phage migration inhibitory factor, which is a potent activator of macrophages and is consid‐
ered to play an important role in cell-mediated immunity, has been found at significantly
higher levels in vitiligo patients compared to controls [95].
10. Dendritic cells
Enhanced populations of CD11c+myeloid dermal dendritic cells and CD207+Langerhans cells
have been observed in the leading edges of vitiligo lesions [75,96,97]. Dendritic cell-LAMP+and
CD1c+sub-populations were also found to be significantly expanded in the lesional edges of
vitiligo skin [75]. More recently, dendritic cell-mediated destruction of melanocytes has been
demonstrated in vivo and in vitro [96,98]. This process was related to the release by stressed
melanocytes of heat-shock protein 70, a molecule which in turn induced the expression of
membrane tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) on dendritic
cells as well as the activation of dendritic cell effector functions directed against stressed
melanocytes exhibiting elevated TRAIL death receptor expression [96,98].
11. Natural killer cells
Alterations in natural killer (NK) cells have been demonstrated in vitiligo patients indicating
a role for them in the pathogenesis of the disease [99]. The percentages of NK cells with
activatory receptors, as denoted by the expression of CD16+CD56+and CD3+CD16+CD56+, are
significantly increased in vitiligo patients compared with the controls, while the percentage of
NK cells expressing the inhibitory receptor CD158a+is significantly reduced.
12. Cytokines
Various studies have implicated cytokine involvement in the pathogenesis of vitiligo [100].
For example, increased serum levels of soluble IL-2 receptor are associated with vitiligo
activity, indicating T cell activation [101], and elevated production of IL-6, which can induce
ICAM-1 expression on melanocytes thereby facilitating leukocyte interactions, and IL-8, which
can attract neutrophils to amplify destructive inflammatory responses, are found in vitiligo
patients [102]. In addition, other pro-inflammatory cytokines including IL-1, IL-4, IFN-gamma
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and TNF-alpha, which are paracrine inhibitors of melanocytes or initiators of apoptosis, are
detected at significantly higher levels in vitiligo patients compared with healthy controls [71,
100,103-105], and IL-17 levels are positively correlated with the extent of body area involve‐
ment [106]. In contrast, the level of TGF-beta, required for the maturation of Treg cells, is
significantly decreased in vitiligo patients compared with controls [106]. Finally, imbalances
of keratinocyte-derived cytokines that affect melanocyte activity and survival are found in
vitiligo lesional skin: significantly lower expression of granulocyte-macrophage colony-
stimulating factor, stem cell factor and endothelin-1 is detected in depigmented vitiligo lesions
compared with normal skin [100].
13. Immuno-regulatory micro RNAs
MicroRNAs (miRNAs) are a class of small non-coding RNAs that negatively regulate gene
expression. Abnormal expression of miRNAs which play crucial roles in regulating immunity
has been reported in vitiligo. In a mouse model of the disease [107], dysregulated miRNAs
included miRNA-146a, which contributes to the regulation of Treg cell function [108] and is
implicated in autoimmune disease development in mice [109], as well as miR-191, which
mediates in the proliferation and survival of melanocytes [110]. In addition, there is an increase
in the expression of immune-regulatory miRNAs miRNA-133b, miRNA-135a, miRNA-9 and
miRNA-1 in the lesional skin of vitiligo patients, suggesting an important role for these in
vitiligo pathogenesis [111].
14. Treatment modalities
Repigmentation  in  vitiligo  patients  receiving  treatment  with  immunosuppressive  agents
indirectly  supports  the  theory  that  immune-mediated  processes  are  involved  in  vitiligo
pathogenesis.  Topically  applied  tacrolimus  (FK506),  a  therapeutic  agent  which  exerts  a
potent immunosuppressive effect on T cells by blocking the action of the cytokine gene-
activating cofactor calcineurin [112], has resulted in successful repigmentation responses in
vitiligo  patients  [113,114]  Topical  corticosteroids,  which  have  anti-inflammatory  and
immunosuppressive actions, are considered to be an effective first-line treatment in children
and adults with segmental or non-segmental vitiligo of recent onset [3,115], and, indeed,
following treatment of vitiligo patients with systemic steroids, a reduction in anti-melano‐
cyte  antibody  levels  and  in  antibody-mediated  anti-melanocyte  cytotoxicity  has  been
demonstrated [116,117].
Psoralen with ultraviolet radiation (PUVA) is used as a second-line therapy for vitiligo [3,118].
Following PUVA treatment, a reduction in the number of Langerhans cells and a decrease in
the expression of vitiligo-associated melanocyte antigens, which could lead to a blocking of
antibody-dependent cell-mediated cytotoxicity against melanocytes, have been noted in
vitiligo patients [119,120]. In addition, ultraviolet radiation can induce the expression of anti-
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inflammatory cytokines, modulate the expression of intercellular adhesion molecule-1, and
induce apoptosis of skin-infiltrating T lymphocytes [121,122].
Despite the many available therapeutic modalities [115,123], repigmentation in the majority
of vitiligo patients is rarely complete or long-lasting, so a better understanding of the precise
aetiology and pathogenesis of the disease is crucial to improving the efficacy of treatment
regimens.
15. Conclusion
As detailed in this chapter, there is strong evidence for the involvement of autoimmunity in
the aetiology and pathogenesis of vitiligo. However, it is most likely that several interacting
factors (Figure 1) are responsible for the clinical manifestations of the disease [124]. Indeed,
although the evidence for the role of immune-related genes in the aetiology of vitiligo is clear
[15], the limited concordance in identical twins [23] indicates that other factors, probably
environmental, are also involved in its development, making the disease complex, polygenic,
and multi-factorial.
Of note is the finding that oxidative-stress in melanocytes [16-18] results in the secretion of
heat-shock protein 70 and chaperoned melanocyte antigens which mediates dendritic cell-
activation with the consequential dendritic cell effector functions then playing a role in the
destruction of melanocytes [96,125]. This has led to the convergence theory of vitiligo aetiology,
which suggests that several factors act synergistically or independently to induce the disap‐
pearance of cutaneous melanocytes (Figure 1) [126]. During the elicitation phase of the disease,
physical trauma to the skin [126], emotional stresses [12], or imbalances of endogenous neural
factors [13], metabolites, cytokines or hormones [87] can lead to oxidative stress within
melanocytes, which then respond by actively secreting heat-shock protein 70 and chaperoned
melanocyte antigens [125]. In the immune activation stage, these ‘danger’ signals promote the
activation of antigen-presenting dendritic cells with the subsequent activation and recruitment
of anti-melanocyte autoreactive cytotoxic T lymphocytes to the skin [19]. Intrinsic damage to
melanocytes could, therefore, be the initiating event in vitiligo development followed by a
destructive secondary anti-melanocyte immune response from cytotoxic T cells [19,126,127].
Notably, 50% of vitiligo patients experience a Koebner phenomenon, whereby vitiligo
develops at a site previously affected by a physical trauma [126]. In addition, different
pathogenic mechanisms could account for the various clinical types of vitiligo: pathogenic
neural factors are usually related to segmental vitiligo, whereas autoimmunity is most often
associated with the non-segmental (generalised) form [2].
As indicated, it is most likely that immune responses in vitiligo are of a secondary nature
following melanocyte damage. Indeed, as several vitiligo-associated autoantigens such as
tyrosinase and gp100 are located intracellularly, it has been suggested that the formation of
neo-antigens due to haptenation, the exposure of cryptic epitopes or the modification of
proteins during apoptosis could account for immune responses against these proteins
[128,129]. In this scenario, after processing by mature Langerhans cells, antigenic peptides are
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presented to T cells which have escaped clonal deletion or to naïve T lymphocytes which are
not tolerised to cryptic epitopes [128,129]. Activated cytotoxic T cells can then attack directly
melanocytes expressing antigenic peptides in the context MHC class I molecules [31,34], and
anti-melanocyte autoantibodies can be produced following the stimulation of B lymphocytes
by activated helper T cells [128].
In summary, autoimmunity has an important role to play in vitiligo development with key
contributions from anti-melanocyte autoreactive cytotoxic T cells [19], T helper 17 cells [74,75],
and Treg cells [77-79].
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